Latest Articles

  • Extreme Language Ultra-High Potency

    The newest generation of small-molecule therapies bring containment needs well beyond those of conventional HPAPIs. What does this mean for the pharma lexicon – and the pharma landscape? read more

  • Under the Spotlight: Agentic AI

    In an interview with Pharmaceutical Outsourcing, ArisGlobal’s Jason Bryant discusses the premise of AI’s next high-profile incarnation, the technology’s potential in late-stage pharma R&D operations, emerging early use cases, and some of the guardrails that need to be in place to ensure trusted, impactful use. read more

  • Safely Scaling Highly Potent API manufacturing

    Ever more drug developers are searching for CDMOs with contamination-limiting capabilities. But how can they know which have these high-potency credentials? read more

  • Five Steps to Smooth Agentic AI Adoption

    In agentic AI-enabled labs, AI goes from individual, one-off applications to comprehensive workflow orchestration. read more